Journal article
Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer
Abstract
BACKGROUND: Cancer increases the risk of thromboembolic events and the risk of recurrent thromboembolic events while on anticoagulation.
OBJECTIVES: To compare the efficacy and safety of low molecular weight heparin (LMWH) and oral anticoagulants (vitamin K antagonist (VKA) and ximelagatran) for the long term treatment of venous thromboembolism (VTE) in patients with cancer.
Authors
Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann H
Journal
, , No. 2,
Publisher
Wiley
DOI
10.1002/14651858.cd006650.pub2
ISSN
1465-1858